{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:41:30Z","timestamp":1783726890853,"version":"3.55.0"},"reference-count":51,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Biofermin Pharmaceutical Co., Ltd.","award":["21K08016"],"award-info":[{"award-number":["21K08016"]}]},{"name":"Biofermin Pharmaceutical Co., Ltd.","award":["18K07986"],"award-info":[{"award-number":["18K07986"]}]},{"name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","award":["21K08016"],"award-info":[{"award-number":["21K08016"]}]},{"name":"Ministry of Education, Culture, Sports, Science and Technology, Japan","award":["18K07986"],"award-info":[{"award-number":["18K07986"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms are distressing for patients with quiescent Crohn\u2019s disease (qCD) and worsen their quality of life. In the present study, we assessed the effect of the probiotic Bifidobacterium bifidum G9-1 (BBG9-1) on the intestinal environment and clinical features in patients with qCD. Eleven patients with qCD, who met the Rome III diagnostic criteria for IBS-D, received BBG9-1 (24 mg) orally three times daily for 4 weeks. Indices of the intestinal environment (fecal calprotectin level and gut microbiome) and clinical features (CD\/IBS-related symptoms, quality of life and stool irregularities) were evaluated before and after treatment. Treatment with BBG9-1 tended to reduce the IBS severity index in the studied patients (p = 0.07). Among gastrointestinal symptoms, abdominal pain and dyspepsia tended to be improved by the BBG9-1 treatment (p = 0.07 and p = 0.07, respectively), and IBD-related QOL showed a significant improvement (p = 0.007). With regard to mental status, the patient anxiety score was significantly lower at the endpoint of BBG9-1 treatment than at the baseline (p = 0.03). Although BBG9-1 treatment did not affect the fecal calprotectin level, it suppressed the serum MCP-1 level significantly and increased the abundance of intestinal Bacteroides in the study patients. The probiotic BBG9-1 is able to improve IBD-related QOL with a reduction of anxiety score in patients with quiescent CD and IBS-D-like symptoms.<\/jats:p>","DOI":"10.3390\/jcm12103368","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T01:57:51Z","timestamp":1683683871000},"page":"3368","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effect of Bifidobacterium bifidum G9-1 on the Intestinal Environment and Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-like Symptoms in Patients with Quiescent Crohn\u2019s Disease: A Prospective Pilot Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1283-9009","authenticated-orcid":false,"given":"Toshihiko","family":"Tomita","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Fukui","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6293-566X","authenticated-orcid":false,"given":"Takuya","family":"Okugawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Mieno","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Nakai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Eda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-932X","authenticated-orcid":false,"given":"Tadayuki","family":"Oshima","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-618X","authenticated-orcid":false,"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9844-642X","authenticated-orcid":false,"given":"Hiroto","family":"Miwa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4110\/in.2017.17.1.25","article-title":"Pathogenesis of inflammatory bowel disease and recent advances in biologic therapies","volume":"17","author":"Kim","year":"2017","journal-title":"Immune Netw."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0002-9270(01)04037-0","article-title":"Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors","volume":"97","author":"Axelsson","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.5056\/jnm15160","article-title":"Prevalence of irritable bowel syndrome-like symptoms in Japanese patients with inactive inflammatory bowel disease","volume":"22","author":"Tomita","year":"2016","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cgh.2016.05.012","article-title":"Negative effects on psychological health and quality of life of genuine irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease","volume":"15","author":"Gracie","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/gutjnl-2012-304066","article-title":"Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation","volume":"63","author":"Bzioueche","year":"2014","journal-title":"Gut"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/ajg.2010.156","article-title":"Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: A real association or reflection of occult inflammation?","volume":"105","author":"Keohane","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1756283X15621230","article-title":"Overlapping irritable bowel syndrome and inflammatory bowel disease: Less to this than meets the eye?","volume":"9","author":"Quigley","year":"2016","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5056\/jnm22027","article-title":"Diarrhea-predominant irritable bowel syndrome-like symptoms in patients with quiescent Crohn\u2019s disease: Comprehensive analysis of clinical features and intestinal environment including the gut microbiome, organic acids, and intestinal permeability","volume":"29","author":"Tomita","year":"2023","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s10620-019-05488-8","article-title":"Presence of irritable bowel syndrome symptoms in quiescent inflammatory bowel disease is associated with high rate of anxiety and depression","volume":"64","author":"Perera","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S2468-1253(20)30300-9","article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: A systematic review and meta-analysis","volume":"5","author":"Fairbrass","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/gut.43.1.29","article-title":"A simple clinical colitis activity index","volume":"43","author":"Walmsley","year":"1998","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tomita, T., Fukui, H., Morishita, D., Mori, S., Oshima, T., Shinzaki, S., and Miwa, H. (2022). Efficacy of serotonin type 3 receptor antagonist ramosetron on diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms in patients with quiescent inflammatory bowel disease: A randomized, double-blind, placebo-controlled trial. J. Clin. Med., 11.","DOI":"10.3390\/jcm11236882"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.5056\/jnm15016","article-title":"Validity and reliability of the Japanese version of the Rome III diagnostic questionnaire for irritable bowel syndrome and functional dyspepsia","volume":"21","author":"Kanazawa","year":"2015","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/apt.17419","article-title":"5-aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn\u2019s disease-A nationwide cohort study","volume":"57","author":"Atia","year":"2023","journal-title":"Aliment. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00535-006-1799-9","article-title":"Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index","volume":"41","author":"Shinozaki","year":"2006","journal-title":"J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1751-0759-1-6","article-title":"Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J)","volume":"1","author":"Kanazawa","year":"2007","journal-title":"Biopsychosoc. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3109\/00365529309098272","article-title":"Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?","volume":"28","author":"Glise","year":"1993","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_20","unstructured":"Ware, J.E., Kosinski, M., Dewey, J.E., and Gandek, B. (2001). How to Score and Interpret Single-Item Health Status Measures: A Manual for Users of the SF-8TM Health Survey, QualityMetric Incorporated."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0016-5085(89)80080-0","article-title":"A new measure of health status for clinical trials in inflammatory bowel disease","volume":"96","author":"Guyatt","year":"1989","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000201455","article-title":"Validation of the Dutch translation of the Inflammatory Bowel Disease Questionnaire (IBDQ): A health-related quality of life questionnaire in inflammatory bowel disease","volume":"58","author":"Russel","year":"1997","journal-title":"Digestion"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1477-7525-1-29","article-title":"The hospital anxiety and depression scale","volume":"1","author":"Snaith","year":"2003","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Fukui, H., Nishida, A., Matsuda, S., Kira, F., Watanabe, S., Kuriyama, M., Kawakami, K., Aikawa, Y., Oda, N., and Arai, K. (2020). Usefulness of machine learning-based gut microbiome analysis for identifying patients with irritable bowels syndrome. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082403"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e20067","DOI":"10.1097\/MD.0000000000020067","article-title":"Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life","volume":"99","author":"Ozer","year":"2020","journal-title":"Medicine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5056\/jnm18071","article-title":"Role of gut microbiota-gut hormone axis in the pathophysiology of functional gastrointestinal disorders","volume":"24","author":"Fukui","year":"2018","journal-title":"J. Neurogastroenterol. Motil."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1056\/NEJMra1600266","article-title":"The human intestinal microbiome in health and disease","volume":"375","author":"Lynch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.cgh.2009.07.016","article-title":"The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis","volume":"7","author":"Sood","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.12787","article-title":"Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome\u2014A 12 week double-blind study","volume":"40","author":"Sisson","year":"2014","journal-title":"Aliment. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: The efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/gut.2003.037747","article-title":"Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine","volume":"53","author":"Kruis","year":"2004","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles","volume":"128","author":"McCarthy","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2982.2005.00650.x","article-title":"The placebo effect in irritable bowel syndrome trials: A meta-analysis","volume":"17","author":"Patel","year":"2005","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12384","DOI":"10.1038\/s41598-018-30943-3","article-title":"Effect of probiotic Bifidobacterium bifidum G9-1 on the relationship between gut microbiota profile and stress sensitivity in maternally separated rats","volume":"8","author":"Fukui","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wang, X., Fukui, H., Ran, Y., Xu, X., Ebisutani, N., Nakanishi, T., Tanaka, Y., Maeda, A., Makizaki, Y., and Tomita, T. (2021). Probiotic Bifidobacterium bifidum G9-1 has a preventive effect on the acceleration of colonic permeability and M1 macrophage population in maternally separated rats. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060641"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/1348-0421.12743","article-title":"Probiotic Bifidobacterium bifidum G9-1 ameliorates phytohemagglutinin-induced diarrhea caused by intestinal dysbiosis","volume":"63","author":"Makizaki","year":"2019","journal-title":"Microbiol. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2011.01.032","article-title":"The role of stress on physiologic responses and clinical symptoms in irritable bowel syndrome","volume":"140","author":"Chang","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1053\/j.gastro.2020.10.066","article-title":"The microbiota-gut-brain axis: From motility to mood","volume":"160","author":"Margolis","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41564-018-0307-3","article-title":"GABA-modulating bacteria of the human gut microbiota","volume":"4","author":"Strandwitz","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7421","DOI":"10.1073\/pnas.1323599111","article-title":"Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut","volume":"111","author":"Joyce","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/19490976.2015.1127483","article-title":"Consequences of bile salt biotransformations by intestinal bacteria","volume":"7","author":"Ridlon","year":"2016","journal-title":"Gut Microbes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/apt.13333","article-title":"Systematic review: Bile acids and intestinal inflammation-luminal aggressors or regulators of mucosal defence?","volume":"42","author":"Pavlidis","year":"2015","journal-title":"Aliment. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Di Vincenzo, F., Puca, P., Lopetuso, L.R., Petito, V., Masi, L., Bartocci, B., Murgiano, M., De Felice, M., Petronio, L., and Gasbarrini, A. (2022). Bile acid-related regulation of mucosal inflammation and intestinal motility: From pathogenesis to therapeutic application in IBD and microscopic colitis. Nutrients, 14.","DOI":"10.3390\/nu14132664"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.tim.2022.08.003","article-title":"Gut microbiome-mediated mechanisms for reducing cholesterol levels: Implications for ameliorating cardiovascular disease","volume":"31","author":"Jia","year":"2023","journal-title":"Trends Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.biotechadv.2017.12.005","article-title":"Importance of microbial defence systems to bile salts and mechanisms of serum cholesterol reduction","volume":"36","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1907272","DOI":"10.1080\/19490976.2021.1907272","article-title":"Butyrate-producing human gut symbiont, Clostridium butyricum, and its role in health and disease","volume":"13","author":"Stoeva","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"974305","DOI":"10.3389\/fimmu.2022.974305","article-title":"Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2784","article-title":"High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3","volume":"15","author":"Labzin","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1084\/jem.180.3.1025","article-title":"Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS","volume":"180","author":"Wurfel","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/nmo.12151","article-title":"FDA and EMA end points: Which outcome end points should we use in clinical trials in patients with irritable bowel syndrome?","volume":"25","author":"Corsetti","year":"2013","journal-title":"Neurogastroenterol. Motil."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3368\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:32:26Z","timestamp":1760124746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/10\/3368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["jcm12103368"],"URL":"https:\/\/doi.org\/10.3390\/jcm12103368","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}